Alvotech Q2 Revenue Falls 38.9%; FDA Decisions Ahead For AVT05 And AVT06 Biosimilars In Q4

Alvotech reported Q2 2026 revenue of a 38.9% decline year over year, indicating a significant contraction in biosimilar sales performance. The company also provided a business update, but the revenue drop is the key negative datapoint that is likely to weigh on near-term sentiment.

Analysis

Alvotech reported Q2 2026 revenue of a 38.9% decline year over year, indicating a significant contraction in biosimilar sales performance. The company also provided a business update, but the revenue drop is the key negative datapoint that is likely to weigh on near-term sentiment.